Sonnet BioTherapeutics Holdings Inc Ordinary Shares SONN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SONN is a good fit for your portfolio.
News
-
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
-
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
-
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
-
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Trading Information
- Previous Close Price
- $1.70
- Day Range
- $1.66–1.84
- 52-Week Range
- $1.08–26.40
- Bid/Ask
- $1.77 / $1.82
- Market Cap
- $5.46 Mil
- Volume/Avg
- 18,325 / 113,544
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://www.sonnetbio.com
Valuation
|
Metric
|
SONN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.12 |
Price/Sales | 14.31 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SONN
|
|---|---|
Quick Ratio | 1.21 |
Current Ratio | 1.74 |
Interest Coverage | — |
Quick Ratio
SONN
Profitability
|
Metric
|
SONN
|
|---|---|
Return on Assets (Normalized) | −182.46% |
Return on Equity (Normalized) | −938.08% |
Return on Invested Capital (Normalized) | −820.59% |
Return on Assets
SONN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jcjhrxzrhp | Bhx | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Knqtpzg | Jqvmw | $104.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tzyznzkb | Tdnzjw | $98.8 Bil | |
MRNA
| Moderna Inc | Jtcycyvv | Fjpb | $38.8 Bil | |
ARGX
| argenx SE ADR | Tshkbvx | Rcsd | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Dqqzhjwh | Jmvy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Msrxwsfb | Jzclg | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gjgdfjm | Kwklkl | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zdnmrrcq | Zzyfpn | $12.4 Bil | |
INCY
| Incyte Corp | Rxsplys | Vcyrsd | $11.9 Bil |